PharmaCielo (PCLO.V) began to sell and distribute their expanded portfolio of medical cannabis extract products regularly produced at its Rionegro facilities today.
The company can now address inquiries customers may have regarding their products based on technical experience, because they now have increased laboratory and processing capabilities, and have begun commercial production of a expanded range of extract products.
“The ability to offer a wide range of bulk products which vary in cannabinoids combination, potency and terpenes content is highly sought-after in the medicinal and wellness sector, as some specific products deliver specific benefits, while others can deliver a full suite of cannabinoid benefits, known as the entourage effect. With our different formulations we are also able to provide customers with the flexibility to formulate their final product according to the individual health and drug delivery system needs,” said David Attard, CEO of PharmaCielo.
The company’s extracts are derived from cultivars developed by their own horticultural arm, and are optimized for year-round Colombian open-field cultivation. Each extract profile reflects the nature of the cultivar.
Their product line has expanded past CBD isolate to include:
- broad spectrum oil
- cbd broad spectrum distillate
- water soluble cbd
- cbd tincture
- cbd distillate tincture
- THC;CBD formulations
- THC distillate
This expansion comes shortly after a multi-year investment in its processing and extraction capabilities. PharmaCielo has started processing part of its formulations at the facility and is now in a position to assess and deliver to meet customer demand at commercial volumes, and at a consistent high-quality, purity and potency levels as required by healthcare standards.
“As we developed the new product range, based on customer and prospect demand, our team placed a greater emphasis on ensuring we added Water Soluble CBD extract to the mix. The development of this product in particular, will enable PharmaCielo to explore integration opportunities with major players in the health-oriented beverage and topical products segments of the market, which have expressed interest in CBD additives,” said Attard.
The company is taking orders for shipments for the remainder of 2020, and anticipates production capacity and shipments volumes increasing into 2021.
—Joseph Morton
